Pharmacological findings on cetiedil.
The molecule of cetiedil (Stratène) has strong papaverine-like and weak atropine-like properties. It brings about peripheral vasodilation at doses which do not affect arterial blood pressure, heart beat and cardiac efficacy; this new drug increases the activity of beta-adrenergic stimulants. There may be different hypotheses to explain the therapeutic effect of cetiedil; beside its papaverinic and synergistic beta-stimulant properties, it increases the haemodynamic coefficient, plays a role in the process of membrane Ca++ exchange and inhibits phosphodiesterase and platelet aggregation.
D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects; D001381:Azepines / Q000494:pharmacology*; D004285:Dogs; D004562:Electrocardiography; D006168:Guinea Pigs; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D051379:Mice; D008833:Microcirculation / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013876:Thiophenes / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D001381:Azepines; D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors; D013876:Thiophenes; D014665:Vasodilator Agents